PLD - Octreotide

pkdiet.com halite himalayan pink salt pkd pld
Octreotide

 

 

 

Octreotide, sandostatin LAR, is a somatostatin analogue. It is the first medication in clinical trials for polycystic liver disease. This long acting form of somatostatin is manufactured by Novartis. It has been used for acromegaly, carcinoid, and other rare endocrine tumors.

 


The very first clinical trial with octreotide LAR was undertaken in Bergamo, Italy at the Mario Negri Center. The Mario Negri Center completed a small Somatostatin trial with 12 patients that determined Octreotide LAR to be safe and reduced cystic kidneys. One participant withdrew from non symptomatic gall stones. Another withdrew from asthenia (Weakness. Lack of energy and strength. Loss of strength.)
There is a current ongoing octreotide clinical trial (yet to be completed) at the Mayo Clinic in Rochester Minnesota USA with 42 participants to determine if long acting injectable octreotide (given once every 28 days) will be useful in reducing severe polycystic liver disease. This last participant inPhase 1 years one and two clinical trial finished April 2010.
A trial in the Netherlands using an analogue of sandostatin (octreotide, lanreotide) is finished.
A third trial in Italy it to determine if octreotide reduces liver cysts. Choose an article about octreotide from the pull down menu below. Somatostatin, octreotide, lanreotide, all similar drugs with different names are all growth hormone inhibitors. Researchers from Spain, scanned the surface of liver cysts with an electron microscope and discovered that the surface contained: hormone receptors, insulin growth hormone receptors and growth hormone receptors. Octreotide inhibits hormones including insulin hormone, growth hormone; and hormones like estrogen.



A cholangiocyte article gives a good reason to avoid hormones, false hormones, estrogen receptors, xenoestrogens, especially with polycystic livers. To read more about xenoestrogens click here.


Octreotide hopefully will prove to significantly reduce liver cysts. Animal proteins seem to increase liver pain, bloating and PLD symptoms. These foods naturally contain growth hormone and some have additional hormones fed to the animals, such as bovine growth hormone, or steroids or estrogen or other hormones. With this latest research paper, of the electron microscope study of liver cysts, if it is possible for one to avoid certain foods this seems best to maintain a minimal of liver cyst growth . Continue to avoid: alcohol, yeast, sugars, concentrated sweets, fat, cream, dairy, milk, cheese, beef, poultry, fried foods, fatty foods, bleach, hormones and caffeine. Some may find this comes about naturally by an aversion to these foods during the recovery phase with a longing for sour, crispy, and truly fresh fruits and vegetables similar to green granny smith apples, crispy greens, sour lemons, grapefruit, and more. Some can taste the metal in canned vegetables served in the hospital food.
Octreotide Clinical Trial The first ever, a clinical trial to see if Sandostatin will diminish liver cysts. This will be completed April 2010.
Octreotide Clinical Trial in Italy. Guiseppe Remuzzi, Mario Negri Institute, Bergamo, Italy: Their study will look at the effect of long-acting somatostatin on disease progression in ADPKD.
Octreotide Clinical Trial in Netherlands. Joost PH Drenth, PhD Radboud University Nijmegen Medical Center.

The Octreotide Clinical Trial will continue into a second phase. This will be continued at the Mayo Clinic in Rochester Minnesota USA.

PHASE I – YEARS 1 & 2
The second phase of the Octreotide study will be open to the original 42 participants who completed phase 1. Phase I is a two year study on octreotide. The first year was blinded; 60% received octreotide; 40% received placebo. I received placebo. The second year of Phase I study all received octreotide. It will be completed the end of March 2010.

PHASE II – YEARS 3 & 4
The second Phase of the octreotide study is underway. Provided is monthly octreotide injectable 28 day for all participants for two full years. The lab work must be covered by participants either through insurance or by self. The cost of once yearly blood work will be around $410. Yearly MRI's will be covered by the study. Participants will need to return to the Mayo at the beginning; in one year and in two year's time. We can fax the 6 month lab work; have it done before we arrive or have it done at the Mayo, whichever is the least expensive for us.

The octreotide trial will no longer check kidney functioning.

 

pkdiet.com polycystic kidney disease polycystic liver diseasecontact us
last updated: Friday, August 19, 2011 7:51 AM